SciTech Development Presentation at the 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference January 13, 2021
SciTech Development, represented by Chief Medical Officer, Brian Leyland-Jones, MB BS, PHD and President & Co-Founder, Earle T. Holsapple III, presented at the 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event took place on January 13, 2021, co-hosted by the China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Fenretinide ST-001 NanoFenretinde Drug Mechanism of Action (MOA)
The mechanism of action for SciTech's patented, lead cancer drug ST-001 nanoFenretinide (nanoparticle sized fenretinide in a phospholipid matrix).
SciTech Development Enabling Proven Cancer Therapies
ST-001 nanoFenretinide, a nanoparticle fenretinide formulation, offers increased hope for cancer sufferers. For Crowdfunding Cancer-Fighting Donations, visit SoundAffects.org
SciTech Presentation & Interview at NIBA Investment Conference in New York City
Earle Holsapple introduces SciTech's patented ST-001 nanoFenretinide technology (nanoparticle sized fenretinide in a phospholipid matrix) to the investment banking community.
SciTech at China BioMed Innovation and Investment Conference (CBIIC) September 2019 in Suzhou, China
Earle Holsapple introduces the company's patented ST-001 nanoFenretinide fenretinide technology to the Chinese investment, biotech and pharmaceutical industry at CBIIC.
SciTech Development: The Company, The Technology and The Investment Opportunity
SciTech presentation including company overview, patented technology, lead drug ST-001 nanoFenretinide fenretinide, addressable markets, competition, key personnel, advisory board, drug product characteristics, fenretinide history, and drug mechanism of action (MOA).
SciTech Development Company Overview
Earle Holsapple, SciTech President, describes the company's patented ST-001 nanoFenretinide technology (nanoparticle sized fenretinide) and the investment opportunity. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | email@example.com